Female fibromyalgia patients: Lower resting metabolic rates than matched healthy controls

Medical Science Monitor

Volumn 12, Issue 7, 2006, Pages

  Lowe, John C ^a   Yellin, Jackie ^a   Honeyman Lowe, Gina ^a  

^a Fibromyalgia Research Foundation   (United States)

Author keywords

Body composition; Fibromyalgia; Free T 4; Free T3; Resting metabolic rate; TSH

Indexed keywords

THYROTROPIN;

ADULT; AGE; ARTICLE; BIOENERGY; BODY COMPOSITION; CALORIMETRY; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FIBROMYALGIA; FREE LIOTHYRONINE INDEX; HUMAN; METABOLIC RATE; PAIN ASSESSMENT; THYROTROPIN BLOOD LEVEL;

ADULT; BASAL METABOLISM; BODY COMPOSITION; CALORIMETRY; CASE-CONTROL STUDIES; ELECTRIC IMPEDANCE; FEMALE; FIBROMYALGIA; HUMANS; MIDDLE AGED;

EID: 33745854765     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: None     Document Type: Article

References (109)

1. Lowe JC: The metabolic treatment of fibromyalgia. Boulder, CO: McDowell Publishing Company, 2000
2. Wilson J, Walton JN: Some muscular manifestations of hypothyroidism. J Neurol Neuros Psychiatr, 1959; 22: 320-24
3. Fessel WJ: Myopathy of hypothyroidism. Ann Rheum Dis, 1968; 27: 590-96
4. Bland JH, Frymoyer JW: Rheumatic syndromes of myxedema. N Engl J Med, 1970; 282: 1171-74
5. Golding D: Hypothyroidism presenting with musculoskeletal symptoms. Ann Rheum Dis, 1970; 29: 10-41
6. Hochberg MC, Koppes GM, Edwards CQ et al: Hypothyroidism presenting as a polymyositis-like syndrome: report of two cases. Arthritis Rheum, 1976; 19: 1363-66
7. Beetham WP Jr: Diagnosis and management of fibrositis syndrome and psychogenic rheumatism. Med Clin North Am, 1979; 63: 433-39
8. Wilke SW, Sheeler LR, Makarowski WS: Hypothyroidism with presenting symptoms of fibrositis. J Rheumatol, 1981; 8: 627-30
9. Delamere JP, Scott DL, Felix-Davies DD: Thyroid dysfunction and rheumatic diseases. J Royal Society Med, 1982; 75: 102
10. Sonkin LS: Endocrine disorders and muscle dysfunction. In: Gelb B, ed. Clinical management of head, neck, and TMJ pain and dysfunction. Philadelphia, PA: WB Saunders Company, 1985; 137-70
11. Awad EA: Histopathological changes in fibrositis. In: Fricton JR, Awad A, eds. Advances in pain research and therapy, vol 17. New York, NY, Raven Press, 1990; 249-58
12. Awad EA: Pathological changes in fibromyalgia. First International Symposium on Myofascial Pain and Fibromyalgia, 1989 May 9; Minneapolis, MN
13. Alajouanine T, Nick J: De l'existence d'une myopathie d'origine hypothyroidienne. Paris Med, 1945; 35: 346
14. Bergouignan M, Vital C, Bataille JM: Les myopathies hypothyroidiennes: aspects cliniques et histopathologiques. Presse Med, 1967; 75: 1551
15. Aarflot T, Bruusgaard D: Association of chronic widespread musculoskeletal complaints and thyroid autoimmunity: results from a community survey. Scand J Prim Health Care, 1996; 14(2): 1111-15
16. Rodolico C, Toscano A, Benvenga S et al: Myopathy as the persistently isolated symptomatology of primary autoimmune hypothyroidism. Thyroid, 1998; 8(11): 1033-38
17. Reilly PA: The differential diagnosis of generalized pain. Baillieres Best Pract Res Clin Rheumatol, 1999; 13(3): 391-401
18. Törüner F: Association of fibromyalgia with Hashimoto's thyroiditis (abstract). European Thyroid Association Annual Meeting; 2004 March 15-17; Istanbul, Turkey
19. Ribeiro LS, Proietti FA: Interrelations between fibromyalgia, thyroid autoantibodies, and depression. J Rheumatol, 2004; 31(10): 2036-40
20. Lowe JC: Thyroid status of 38 fibromyalgia patients: implications for the etiology of fibromyalgia. Clin Bull Myofascial Ther, 1997; 2(1): 47-64
21. Lowe JC, Reichman A, Honeyman GS, Yellin J: Thyroid status of fibromyalgia patients (abstract). Clin Bull Myofascial Ther, 1998; 3(1): 69-70
22. Eisinger J: Hypothyrod'die et fibromyalgie: indications d'une double hormonothérapie thyroid'dienne. Lyon Méditerranée Médical, 1999; 35: 31-36
23. Gerwin R: A study of 96 subjects examined both for fibromyalgia and myofascial pain. J Musculoskel Pain, 1995; 3(Suppl.1): 121
24. Shiroky JB, Cohen M, Ballachey M-L, Neville C: Thyroid dysfunction in rheumatoid arthritis: a controlled prospective survey. Ann Rheumat Dis, 1993; 52: 454-56
25. Neeck G, Riedel W: Thyroid function in patients with fibromyalgia syndrome. J Rheumatol, 1992; 19: 1120-22
26. Ferraccioli G, Cavalieri F, Salaffi F et al: Neuroendocrinologic findings in primary fibromyalgia (soft tissue chronic pain syndrome) and in other chronic rheumatic conditions (rheumatoid arthritis, low back pain). J Rheumatol, 1990; 17: 869-73
27. Hershman JM: Hypothalamic and pituitary hypothyroidism. In: Bastenie PA, Bonnyns M, VanHaelst L, eds. Progress in the diagnosis and treatment of hypothyroid conditions. Amsterdam: Excerpta Medica, 1980
28. Tunbridge WMG, Evered DC, Hall R: The spectrum of thyroid disease in a community survey. Clin Endocrinol, 1977; 7: 481-93
29. Eisinger J, Arroyo PH, Calendini C et al: Anomalies biologiques au cours des fibromylalgies: III. Explorations endocriniennes. Lyon Mé diterranée Médical, 1992; 28: 858-60
30. Gerwin R: A study of 96 subjects examined both for fibromyalgia and myofascial pain. J Musculoskel Pain, 1995; 3(Suppl.1): 121
31. Shiroky JB, Cohen M, Ballachey M-L, Neville C: Thyroid dysfunction in rheumatoid arthritis: a controlled prospective survey. Ann Rheumat Dis, 1993; 52: 454-56
32. Forslind K, Fredricksson E, Nived O: Does primary fibromyalgia exist? Brit J Rheumatol, 1990; 29: 368-70
33. Lowe JC, Yellin J: The relationship of fibromyalgia syndrome to inadequate thyroid hormone regulation. Thyroid Science, 2006; 1(1): 10-22
34. 1 gene: do they underlie euthyroid fibromyalgia? Med Hypotheses, 1997; 48(2): 125-35
35. Eisinger J: Metabolic abnormalities in fibromyalgia. Clin Bull Myofascial Ther, 1998; 3(1): 3-21
36. 3 therapy with 77 euthyroid female fibromyalgia patients. Clin Bull Myofascial Ther, 1997; 2(1): 35-37
37. 3. J Myofascial Ther, 1994; 1(2): 16-29
38. 4 and desiccated thyroid. J Myofascial Ther, 1995; 1(4): 26-31
39. Honeyman GS: Metabolic therapy for hypothyroid and euthyroid fibromyalgia: two case reports. Clin Bull Myofascial Ther, 1997; 2(4): 19-49
40. Teitelbaum J, Bird B: Effective treatment of severe chronic fatigue: a report of a series of 64 patients. J Musculoskel Pain, 1995; 4: 91-110
41. 3 therapy for euthyroid fibromyalgia: a double-blind, placebo-controlled response-driven crossover study. Clin Bull Myofascial Ther, 1997; 2(2/3): 31-57
42. 3) treatment of euthyroid fibromyalgia: a small-n replication of a double-blind placebo-controlled crossover study. Clin Bull Myofascial Ther, 1997; 2(4): 71-88
43. 3 therapy for euthyroid fibromyalgia: a double-blind, placebo-controlled crossover study. Clin Bull Myofascial Ther, 1997; 2(2/3): 91-124
44. Teitelbaum J, Bird B, Greenfield RM et al: Effective treatment of CFS and FMS: a randomized, double-blind placebo controlled study. J Chron Fatigue Synd, 2001; 8(2): 3-28
45. 3 (triiodothyronine) on geloid masses found in patients with both fibromyalgia and myofascial pain: double-blinded, crossover N of 1 clinical study. Myalgies Internat, 2001; 2-2: 8-18
46. Lowe JC, Reichman AJ, Yellin J: A case-control study of metabolic therapy for fibromyalgia: long-term follow-up comparison of treated and untreated patients. Clin Bull Myofascial Ther, 1998; 3(1): 65-79
47. Liverini G, Iossa S, Barletta A: Relationship between resting metabolism and hepatic metabolism: effect of hypothyroidism and 24 hours fasting. Horm Res, 1992; 38(3-4): 154-59
48. Johnson AB, Webber J, Mansell P et al: Cardiovascular and metabolic responses to adrenaline infusion in patients with short-term hypothyroidism. Clin Endocrinol (Oxf), 1995; 43(6): 747-51
49. Kaplan MM, Swartz SL, Larsen PR: Partial peripheral resistance to thyroid hormones. Am J Med, 1981; 70: 1115-121
50. Burckhardt CS, Clark SR, Bennett RM: The fibromyalgia impact questionnaire: development and validation. J Rheumatol, 1991; 18(5): 728-33
51. Meijer GAL, Westerterp KR, Saris WHM, Hoor FT: Sleeping metabolic rate in relation to body composition and the menstrual cycle. Am J Clin Nutr, 1992; 55: 637-40
52. Web P: 24-hour energy expenditure and the menstrual cycle. Am J Clin Nutr, 1986; 44: 614-19
53. Weir JB: New methods for calculating metabolic rate with special reference to protein metabolism. J Physiol, 1948; 109: 1-9
54. Melanson EL, Coelho LB, Tran ZV et al: Validation of the BodyGem hand-held calorimeter. Int J Obes Relat Metab Disord, 2004; (11): 1479-84
55. St-Onge MP, Rubiano F, Jones A Jr, Heymsfield SB: A new hand-held indirect calorimeter to measure postprandial energy expenditure. Obes Res, 2004; 12(4): 704-9
56. Stewart CL, Goody CM, Branson R: Comparison of two systems of measuring energy expenditure. JPEN J Parenter Enteral Nutr, 2005; 29(3): 212-17
57. Compher C, Hise M, Sternberg A, Kinosian BP: Comparison between Medgem and Deltatrac resting metabolic rate measurements. Eur J Clin Nutr, 2005; 59(10): 1136-41
58. Ravussin E, Bogardus C: A brief overview of human energy metabolism and its relationship to essential obesity. Am J Clin Nutr, 1992; 55: 242S-45S
59. Webb P: Energy expenditure and fat-free mass in men and women. Am J Clin Nutr, 1981; 34: 1816-26
60. Ravussin E, Burnand B, Schutz Y, Jéquier E: Twenty-four hour energy expenditure and resting metabolic rate in obese, moderately obese, and control subjects. Am J Clin Nutr, 1982; 35: 566-73
61. Owen OE, Holup JI, D'Alessio DA et al: A reappraisal of the caloric requirements of men. Am J Clin Nutr, 1987; 46: 875-85
62. Cunningham JJ: A reanalysis of the factors influencing basal metabolic rate in normal adults. Am J Clin Nutr, 1980; 33: 2372-74
63. Segal KR, Lacayanga I, Dunaif A et al: Impact of body fat and percent fat on metabolic rate and thermogenesis in men. Am J Physiol, 1989; 256: E573-79
64. Johnstone AM, Murison SD, Duncan JS et al: Factors influencing variation in basal metabolic rate include fat-free mass, fat mass, age, and circulating thyroxine but not sex, circulating leptin, or triiodothyronine. Am J Clin Nutr, 2005; 82(5): 941-48
65. Ravussin E: Energy metabolism in obesity. Studies in the Pima Indians. Diabetes Care, 1993; 16(1): 232-38
66. th ed. Philadelphia, PA, WB Saunders Company, 1979
67. Olsen NJ, Park JH: Skeletal muscle abnormalities in patients with fibromyalgia. Am J Med Sci, 1998; 315(6): 351-58
68. Skaggs SR, Crist DM: Exogenous human growth hormone reduces body fat in obese women. Horm Res, 1991; 35(1): 19-24
69. Binnerts A, Swart GR, Wilson JH et al: The effect of growth hormone administration in growth hormone deficient adults on bone, protein, carbohydrate and lipid homeostasis, as well as on body composition. Clin Endocrinol (Oxf), 1992; 37(1): 79-87
70. Tenover JL: Experience with testosterone replacement in the elderly. Mayo Clin Proc, 2000; 75(Suppl.): S77-81
71. Bhasin S, Woodhouse L, Storer TW: Proof of the effect of testosterone on skeletal muscle. Endocrinol, 2001; 170(1): 27-38
72. Poehlman ET, Goran MI, Gardner AW et al: Determinants of decline in resting metabolic rate in aging females. Am J Physiol, 1963; 264: E540
73. Van Pelt RE, Jones PP, Davy KP et al: Regular exercise and the age-related decline in resting metabolic rate in women. J Clin Endocrinol Metab, 1997; 82(10): 3208-12
74. Goran MI, Kaskoun MC, Johnson RK: Determinants of resting energy expenditure in young children. J Pediatr, 1994; 125: 362-67
75. Gilliat-Wimberly M, Manore MM, Woolf K et al: Effects of habitual physical activity on the resting metabolic rates and body compositions of women aged 35 to 50 years. J Am Diet Assoc, 2001; 101(10): 1181-88
76. Roberts SB, Savage S, Coward WA et al: Energy expenditure and intake in infants born to lean and overweight mothers. N Engl J Med, 1988; 318: 461-66
77. Ravussin E, Lillioja S, Knowler WC et al: Reduced rate of energy expenditure as a risk factor for body weight gain. N Engl J Med, 1988; 318: 467-72
78. Buscemi S, Verga S, Caimi G, Cerasola G: Low relative resting metabolic rate and body weight gain in adult Caucasian Italians. Int J Obes (Lond), 2005; 29(3): 287-91
79. Tagliaferri M, Berselli ME, Caloň G et al: Subclinical hypothyroidism in obese patients: relation to resting energy expenditure, serum leptin, body composition, and lipid profile. Obesity Res, 2001; 9: 196-201
80. Al-Adsani H, Hoffer JL, Enrique Silva JE: Resting energy expenditure is sensitive to small dose changes in patients on chronic thyroid hormone replacement. J Clin Endocrinol Metab, 1997; 82(4): 1118-25
81. Stenlöf K, Sjöström L, Fagerberg B et al: Thyroid hormones, procollagen III peptide, body composition and basal metabolic rate in euthyroid individuals. Scand J Clin Lab Invest, 1993; 53(8): 793-803
82. Johansen K, Hansen JM, Skovsted L: The preferential role of triiodothyronine in the regulation of basal metabolic rate in hyper- and hypothyroidism. Acta Med Scand, 1978; 204(5): 357-59
83. Isozaki O, Tsushima T, Sato K: Triiodothyronine binding immunoglobulin in a euthyroid man without apparent thyroid disease; its properties and effects on triiodothyronine metabolism. Acta Endocrinol (Copenh), 1985; 108(4): 498-503
84. Wortsman J, Premachandra BN, Williams K et al: Familial resistance to thyroid hormone associated with decreased transport across the plasma membrane. Ann Intern Med, 1983; 98(6): 904-9
85. Henry JL, Sessle BJ, Lucier GE, Hu JW: Effects of substance P on nociceptive and non-nociceptive trigeminal brain stem neurons. Pain, 1980; 8: 33-45
86. Malmberg A, Yaksh T: Hyperalgesia mediated by spinal glutamate or substance P receptor blocked by spinal cyclooxygenase inhibition. Science, 1992; 257: 1276-79
87. Jonassen JA, Mullikin-Kirkpatrick D, McAdam A, Leeman SE: Thyroid hormone status regulates preprotachykinin-A gene expression in male rat anterior pituitary. Endocrinology, 1993; 121: 1555-61
88. Jones PM, Ghatei MA, Wallis SC, Bloom SR: Differential response to neuropeptide Y, substance P, and vasoactive intestinal polypeptide in the rat anterior pituitary gland to alterations in thyroid hormone status. J Endocrinol, 1994; 143: 393-97
89. Savard P, Blanchard LM, Merand Y et al: Influences of both thyroid and bovine growth hormones on substance P, thyrotropin-releasing hormone, serotonin and 5-hydroxyindoleacetic acid contents in the lumbar spinal cord of developing rats. Brain Res, 1984; 315(1): 105-10
90. Too HP, Marriott DR, Wilkin GP: Preprotachykinin-A and substance P receptor (NK1) gene expression in rat astrocytes in vitro. Neuroscience Letters, 1994; 182(2): 185-87
91. Lam KS, Lechan RM, Minamitani N et al: Vasoactive intestinal peptide in the anterior pituitary is increased in hypothyroidism. Endocrinology, 1989; 124: 1077-84
92. Mendelson SC, Quinn JP: Characterization of potential regulatory elements within the rat preprotachykinin-A promoter. Neuroscience Letters, 1995; 184(2): 125-28
93. Savard P, Merand Y, Bedard P et al: Comparative effects of neonatal hypothyroidism and euthyroidism on TRH and substance P content of lumbar spinal cord in saline and PCPA-treated rats. Brain Res, 1983; 277(2): 263-68
94. Vaerřy H, Helle R, Řystein F et al: Elevated CSF levels of substance P and high incidence of Raynaud phenomenon in patients with fibromyalgia: new features for diagnosis. Pain, 1988; 32: 21-26
95. Russell IJ, Orr MD, Littman B et al: Elevated cerebrospinal levels of substance P in patients with the fibromyalgia syndrome. Arthritis Rheum, 1994; 37: 1593-601
96. Welin M, Bragee B, Nyberg F et al: Elevated substance P levels are contrasted by a decrease in met-enkephalin-arg-phe levels in CSF from fibromyalgia patients. J Musculoskeletal Pain, 1995; 3(Suppl.1): 4
97. Bradley LA, Alberts KR, Alarcon GS et al: Abnormal brain regional cerebral blood flow (rCBF) and cerebrospinal fluid (CSF) levels of substance P (SP) in patients and non-patients with fibromyalgia (FM). Arthritis Rheum, 1996; 39(Suppl.): S212
98. Sehnert KW, Croft AC: Basal metabolic temperature vs. laboratory assessment in "posttraumatic hypothyroidism." J Manipulative Physiol Ther, 1996; 19(1): 6-12
99. Barnes B: Basal temperature versus basal metabolism. JAMA, 1942; 119: 1072-74
100. Wyss F, Studer H: Peripheral euthyrotic hypometabolism or secondary hypothyroidism. Schweiz Med Wochenschr, 1963; 93: 1680-83
101. Lowe JC, Honeyman-Lowe G: Thyroid disease and fibromyalgia syndrome. Lyon Méditerranée Médical: Médecine du Sud-Est, 2000; 36(1): 15-17
102. Barrett-Connor E: Nutrition epidemiology: how do we know what they ate? Am J Clin Nutr, 1991; 54(Suppl.1): 182S-87S
103. Prentice AM, Black AE, Coward WA et al: High levels of energy expenditure in obese women. Br Med J, 1986; 292: 983-87
104. Westerterp KR, Saris WH, van Es M, ten Hoor F: Use of the doubly labeled water technique in humans during heavy sustained exercise. J Appl Physiol, 1986; 61(6): 2162-67
105. Haggarty P, McGaw BA, Maughan RJ, Fenn C: Energy expenditure of elite female athletes measured by the doubly-labeled water method. Proc Nutr Soc, 1988; 47: 35A
106. Singh J, Prentice AM, Diaz E et al: Energy expenditure of Gambian women during peak agricultural activity measured by the doubly-lableled water method. Br J Nutr, 1989; 62: 315-29
107. Livingstone MBE, Prentice AM, Strain JJ et al: Accuracy of weighted dietary records in studies of diet and health. Br Med J, 1990; 300: 708-12
108. Bandini LG, Schoeller DA, Dietz WH: Energy expenditure in obese and nonobese adolescents. Pediatr Res, 1990; 27: 198-202
109. Schoeller DA: How accurate is self-reported dietary energy intake? Nutr Rev, 1990; 48(10): 373-79